PYC THERAPEUTICS LIMITED — Director's Dealing 2020

Dec 15, 2020

16 December 2020

Appendix 3X - Initial Director's Interest Notice

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) submits the following Appendix 3X - Initial Director's Interest Notice for Mr Sahm Nasseri, upon his appointment as Chief Executive officer in the US.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

ENDS

For further information, please contact:

Rohan Hockings CEO Info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994 pyctx.com PYC Therapeutics Limited ACN 098 391 961

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PYC THERAPEUTICS LIMITED
ACN	098 391 961

We, PYC Therapeutics Limited give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	SAHM NASSERI
Date of Appointment	10 December2020

Part 1 - Director's relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Number & class of securities

32,000,000 unlisted options exercisable by the payment of $0.15 on or before 30 November 2023 subject to vesting conditions

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstancesgiving rise to the relevant interest.	Number & class of SecuritiesNIL

Part 3 – Director's interests in contracts

Detail of contract	NIL
Nature of interest
Name of registered holder(if issued securities)
No.and class of securities to whichinterest relates

+ See chapter 19 for defined terms.